Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation

Psoriatic disease, encompassing psoriasis and psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus. Current evidence regarding dipeptidyl peptidase-4 inhibitors’ effects on psoriatic disease presents conflicting findings, with the impact on psoriatic arthritis remaining unexplored. This study aimed to investigate the association between dipeptidyl peptidase-4 inhibitors use and psoriatic disease risk in diabetic patients. A nationwide population-based cohort study was conducted using Taiwan’s National Health Insurance Research Database (2009–2021), including 78,865 patients with type 2 diabetes mellitus: 15,773 dipeptidyl peptidase-4 inhibitors users and 63,092 matched controls. Primary outcomes were incident psoriasis and psoriatic arthritis. During a median follow-up of 7.08 years, 393 cases developed psoriatic disease: 51 cases in the dipeptidyl peptidase-4 inhibitors cohort vs 342 cases in controls. Dipeptidyl peptidase-4 inhibitors therapy was associated with significantly lower psoriatic disease risk (adjusted hazard ratio 0.583, 95% confidence interval 0.430–0.696). Individual dipeptidyl peptidase-4 inhibitors demonstrated varying protective effects, with alogliptin showing the strongest protection. In vitro experiments confirmed that dipeptidyl peptidase-4 inhibitors significantly attenuated inflammatory responses in human skin cells. This large-scale nationwide study demonstrates that dipeptidyl peptidase-4 inhibitors use is associated with a 41.7% lower risk in psoriatic disease in diabetic patients.

• Publication year

  2025

• Venue

  Acta Dermato-Venereologica

• Publication date

  2025-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.2340/actadv.v105.44343PMID 41222230PMCID 12621422
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CXCL10 secreted by SPRY1-deficient epidermal keratinocytes fuels joint inflammation in psoriatic arthritis via CD14 signaling

  2025cited by this paper
• Dipeptidyl peptidase-4 inhibitors and the risk of chronic inflammatory skin diseases in type 2 diabetes mellitus in Taiwan: a nationwide population-based cohort study.

  2024cited by this paper
• Incidence, Prevalence, and Mortality of People with Psoriasis and Psoriatic Arthritis in Taiwan: A Nationwide Cohort Study

  2022influential reference
• Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease

  2022cited by this paper
• DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway

  2022cited by this paper
• The bidirectional association between type 2 diabetes and psoriasis: Two retrospective cohort studies

  2020cited by this paper
• Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohort study

  2020cited by this paper
• Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients with Diabetes: A Double-Blind Randomized Controlled Trial

  2019cited by this paper
• Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study

  2018influential reference
• Psoriasis and New-onset Depression: A Danish Nationwide Cohort Study.

  2016cited by this paper
• Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial

  2016cited by this paper
• Validity of in-hospital mortality data among patients with acute myocardial infarction or stroke in National Health Insurance Research Database in Taiwan.

  2015cited by this paper
• Validation of Acute Myocardial Infarction Cases in the National Health Insurance Research Database in Taiwan

  2014cited by this paper
• Sitagliptin for severe psoriasis

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study

  2014cited by this paper
• Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis

  2011cited by this paper
• Psoriasis

  2010cited by this paper
• Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.

  2010cited by this paper
• CD26/dipeptidyl‐peptidase IV in psoriatic skin: upregulation and topographical changes

  2008cited by this paper
• Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.

  2008cited by this paper
• Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

  2007cited by this paper
• Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV

  1998cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper

• No citing papers are available for this paper.